Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025
Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has scheduled its Q2 2025 financial results and business update for August 14, 2025, before Nasdaq CM market opening.
The company will host a conference call and webcast at 14:30 CET/08:30 EST on the same day, where Executive Management will present the results and take questions. Participants must pre-register to receive dial-in details and a PIN code. The webcast recording will be available on Evaxion's website after the event.
Evaxion (NASDAQ: EVAX), una società TechBio in fase clinica specializzata nello sviluppo di vaccini potenziati dall'IA, ha programmato la pubblicazione dei risultati finanziari e aggiornamento operativo del 2° trimestre 2025 per il 14 agosto 2025, prima dell'apertura del mercato Nasdaq CM.
La società terrà una conference call e un webcast alle 14:30 CET/08:30 EST lo stesso giorno, durante i quali il management esecutivo presenterà i risultati e risponderà alle domande. I partecipanti devono preregistrarsi per ricevere i dettagli di accesso e un codice PIN. La registrazione del webcast sarà disponibile sul sito di Evaxion dopo l'evento.
Evaxion (NASDAQ: EVAX), una compañía TechBio en fase clínica centrada en el desarrollo de vacunas impulsadas por IA, ha programado sus resultados financieros y actualización comercial del 2T 2025 para el 14 de agosto de 2025, antes de la apertura del mercado Nasdaq CM.
La compañía celebrará una conferencia telefónica y una retransmisión web a las 14:30 CET/08:30 EST ese mismo día, en la que la dirección ejecutiva presentará los resultados y responderá preguntas. Los participantes deben preregistrarse para recibir los datos de acceso y un código PIN. La grabación del webcast estará disponible en la web de Evaxion tras el evento.
Evaxion (NASDAQ: EVAX)은 AI 기반 백신 개발에 주력하는 임상 단계의 테크바이오(TechBio) 기업으로, 2025년 2분기 실적 및 사업 업데이트를 2025년 8월 14일 나스닥 CM 시장 개장 전에 발표할 예정입니다.
회사는 같은 날 14:30 CET/08:30 EST에 컨퍼런스 콜 및 웹캐스트를 진행하며, 경영진이 실적을 발표하고 질의응답을 진행합니다. 참가자는 전화 접속 정보와 PIN 코드를 받기 위해 사전 등록해야 합니다. 웹캐스트 녹화는 행사 후 Evaxion 웹사이트에서 제공됩니다.
Evaxion (NASDAQ: EVAX), une société TechBio en phase clinique spécialisée dans le développement de vaccins assisté par IA, a prévu la publication de ses résultats financiers et mise à jour opérationnelle du 2e trimestre 2025 le 14 août 2025, avant l'ouverture du marché Nasdaq CM.
La société tiendra une conférence téléphonique et une webdiffusion le même jour à 14:30 CET/08:30 EST, au cours desquelles la direction présentera les résultats et répondra aux questions. Les participants doivent se préenregistrer pour recevoir les informations d'appel et un code PIN. L'enregistrement du webinaire sera disponible sur le site d'Evaxion après l'événement.
Evaxion (NASDAQ: EVAX), ein klinisch tätiges TechBio-Unternehmen, das sich auf KI-gestützte Impfstoffentwicklung spezialisiert hat, hat seine Finanzergebnisse und Geschäftsaktualisierung für das 2. Quartal 2025 für den 14. August 2025, vor Börsenöffnung am Nasdaq CM, terminiert.
Das Unternehmen wird am selben Tag um 14:30 CET/08:30 EST eine Telefonkonferenz und ein Webcast abhalten, bei dem das Executive Management die Ergebnisse vorstellen und Fragen beantworten wird. Teilnehmer müssen sich vorab registrieren, um Einwahldaten und eine PIN zu erhalten. Die Aufzeichnung des Webcasts wird nach der Veranstaltung auf der Website von Evaxion verfügbar sein.
- None.
- None.
COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2025 financial results on Thursday August 14, 2025, before opening of the Nasdaq CM.
Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.
To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.
To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About EVAXION
Evaxion A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
When will Evaxion (NASDAQ: EVAX) release Q2 2025 earnings?
What time is Evaxion's Q2 2025 earnings call?
How can investors join Evaxion's Q2 2025 earnings call?
Where can I find the replay of Evaxion's Q2 2025 earnings call?
